Miniatura

Fitxers

694442.pdf (856.33 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020

Llicència de publicació

cc by (c) Sureda et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173318

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41409-019-0693-z

Resum

Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.

Matèries

Limfomes, Cèl·lules mare

Matèries (anglès)

Lymphomas, Stem cells

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SUREDA, Anna, CHABANNON, Christian, MASSZI, Tamás, POHLREICH, David, SCHEID, Christof, THIEBLEMONT, Catherine, WAHLIN, Björn e., SAKELLARI, Ioanna, RUSSELL, Nigel, JANIKOVA, Andrea, DABROWSKA-IWANICKA, Anna, TOUZEAU, Cyrille, ESQUIROL, Albert, JANTUNEN, Esa, VAN DER WERF, Steffie, BOSMAN, Paul, BOUMENDIL, Ariane, LIU, Qianying, CELANOVIC, Marina, MONTOTO, Silvia, DREGER, Peter. Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. _Bone Marrow Transplantation_. 2020. Vol. 55, núm. 613-622. [consulta: 27 de gener de 2026]. ISSN: 0268-3369. [Disponible a: https://hdl.handle.net/2445/173318]

Exportar metadades

JSON - METS

Compartir registre